OR WAIT null SECS
Considering Patient Priorities in PsA Care, with Philip Mease, MD
Mease discussed recent research on what matters in PsA care between patients and clinicians.
New research, led by Philip Mease, MD, Clinical Professor, University of Washington School of Medicine and Director, Rheumatology Research, Swedish Medical Center, has highlighted differences between patient and clinician priorities in the management of psoriatic arthritis (PsA).
Mease and colleagues put together a list of PsA attributes important to 4 focus groups of patients with PsA and a steering group of physicians and surveyed clinicians and patients to denote importance of attributes on the list. They found that both groups held attributes of arthritis, disease activity, pain, fatigue, physical function, and spine symptoms as highest priorities, but also found that patients ranked attributes such as access to care, daily activities, stiffness, future health uncertainty, and sleep quality as more important while clinicians ranked specific disease skin and joint manifestations, comorbidities, structural damage, and disease management goals as more important.
HCPLive spoke with Mease to learn more about the research and what the investigators learned from the study. Mease noted his surprise to see some of the attributes that patients considered more important and shared how some of the study’s findings have impacted the way he cares for patients.
“What this has done for me is to try to carve out a part of our clinic visit that isn't just focused on, have you had any adverse effects? What's your pain level like? How many swollen joints do you have? But sitting back and [asking], are there other concerns that you have or questions that we haven't had a chance to address during our various conversations and just trying to have a few minutes [with them to open up],” Mease said.
Relevant disclosures include AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead Sciences, Genentech, Janssen, Novartis, Pfizer Inc, Sun and UCB.
